Premium
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide
Author(s) -
Oka Satoko,
Ono Kazuo,
Nohgawa Masaharu
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12740
Subject(s) - lenalidomide , pomalidomide , multiple myeloma , bortezomib , medicine , refractory (planetary science) , thalidomide , oncology , physics , astrobiology
Summary What is known and objectives Optimal strategies for treating patients with very advanced relapsed and refractory multiple myeloma (RRMM) have not been clarified. Case summary A 80‐year‐old patient with RRMM experienced extramedullary relapse following treatment with bortezomib, lenalidomide and pomalidomide. However, he achieved very good partial remission after retreatment with lenalidomide. What is new and conclusion This report illustrates that patients with very advanced RRMM can still respond to prior therapy even after being exposed and refractory to several agents. Considering the depth or duration of response to prior treatment, “retreatment” may improve the outcome of frail RRMM.